ArticleBMC complementary medicine and therapies2025
Exploring the neuroprotective mechanisms of Jiawei Suanzaoren decoction in depression: insights from network pharmacology and molecular docking.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundDepression is a prevalent and debilitating neuropsychiatric disorder, often associated with neuroinflammation, oxidative stress, and neuronal apoptosis. Jiawei Suanzaoren (JWSZR), a traditional Chinese medicine (TCM) formulation, has demonstrated potential in alleviating depressive symptoms. However, its precise molecular mechanisms remain unclear. This study aims to elucidate the neuroprotective effects of JWSZR in depression using network pharmacology, molecular docking, and in vitro experimental validation.
methodsActive compounds of JWSZR were identified using the TCMSP and HERB databases, and depression-related targets were retrieved from GeneCards, DisGeNET, and OMIM. A protein-protein interaction (PPI) network was constructed, followed by functional enrichment analyses, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Molecular docking was employed to predict the interactions between JWSZR's active components and key target proteins. Furthermore, in vitro experiments were performed using corticosterone (CORT)-induced PC12 cell model to validate the neuroprotective effects of JWSZR, assessing cell viability and apoptosis rates.
resultsNetwork pharmacology and molecular docking revealed that JWSZR exerts neuroprotective effects through multiple targets, including estrogen receptor ESR2, HSP90AA1, and STAT1. These targets regulate immune responses, inflammatory pathways, and cell survival. In vitro, JWSZR significantly improved cell viability and reduced apoptosis in CORT-treated PC12 cells, indicating its potential to protect against depression-related neurodegeneration.
conclusionThis study provides novel insights into the neuroprotective mechanisms of JWSZR in depression, suggesting that it may act through multi-target interactions involving immune modulation and apoptosis inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.